Nuvo Research® Sells PENNSAID® 2% U.S. Rights for US$45 Million to Horizon Pharma

MISSISSAUGA, ON, Oct. 17, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has completed the sale of its PENNSAID 2% U.S. sales and marketing rights to Horizon Pharma plc (NASDAQ:HZNP) for a cash payment ofUS$45 million (CDN$50 million) which was payable on closing.

Please click here to view the full press release.